The Trust Layer for Market Analysts

Abbott Laboratories (ABT) is showing a mixed but overall positive fundamental picture, with consistent revenue and operating income growth supported by strong performance in its medical device and diagnostics segments. While costs are rising, the company's sustained innovation and dividend history (54 consecutive years of growth) suggest a resilient business. The current dividend yield of approximately 2.7% is considered attractive given the company's stability and growth prospects, making it a potentially solid investment for income-focused investors, especially if the stock sees a dip towards the $80 range.